Baricitinib, an oral dual JAK1/2 inhibitor, has proven effective in rheumatoid arthritis (RA) by blocking IL−6/JAK/STAT signaling and reducing structural joint damage. This evidence concerns the gene IL6 and rheumatoid arthritis.